AmerisourceBergen 2011 Annual Report Download - page 23

Corporate Information
Shareholder Services
Our transfer agent, BNY Mellon, can help you with
a variety of shareholder services, including:
• Change of address
• Lost stock certificates
• Stock transfer
• Account consolidation
BNY Mellon Can Be Reached At:
Telephone: [phone], or TDD 800-231-5469
Outside U.S.: 201-680-6578, or TDD 201-680-6610
Internet: www.bnymellon.com/shareowner/equityaccess
Mail: AmerisourceBergen Corporation
c/o BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
Additional Information
Financial documents, such as our Annual Report
on Form 10-K, quarterly reports on Form 10-Q,
the Company’s Code of Ethics and Business Conduct,
and other reports and filings may be obtained from
the Company website at www.amerisourcebergen.com,
or by calling the Company’s Investor Relations Department
at 610-727-7000.
Investor Relations
Shareholders, security analysts, portfolio managers, and
other investors desiring further information about the
Company should contact Barbara Brungess,Vice President,
Corporate and Investor Relations at 610-727-7199, or
[e-mail].
Annual Meeting
AmerisourceBergen shareholders are invited to attend
our annual meeting on March 1, 2012 at 3:30 p.m. Eastern
Time at The Four Seasons Hotel, One Logan Square,
Philadelphia, Pennsylvania.
Independent Registered Public Accounting Firm
Ernst &Young LLP, Philadelphia, Pennsylvania
Stock Listing
AmerisourceBergen Corporation is listed on The New
York Stock Exchange under the symbol ABC.
21
Certain of the statements contained in this summary annual report are
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934.These statements are based on management’s current
expectations and are subject to uncertainty and change in circumstances.
Among the factors that could cause actual results to differ materially
from those projected, anticipated or implied are the following:
changes in pharmaceutical market growth rates; the loss of one or
more key customer or supplier relationships; changes in customer
mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers’
pricing and distribution policies or practices; adverse resolution of
any contract or other dispute with customers or suppliers; federal
and state government enforcement initiatives to detect and prevent
suspicious orders of controlled substances and the diversion of
controlled substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations
governing the marketing, sale and purchase of pharmaceutical
products or any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies,
including under Medicaid and Medicare; changes in regulatory or
clinical medical guidelines and/or labeling for the pharmaceutical
products we distribute, including certain anemia products; price
inflation in branded pharmaceuticals and price deflation in generics;
greater or less than anticipated benefit from launches of the generic
versions of previously patented pharmaceutical products; significant
breakdown or interruption of our information technology systems;
our inability to continue to implement an enterprise resource
planning (ERP) system to handle business and financial processes
and transactions (including processes and transactions relating to our
customers and suppliers) of AmerisourceBergen Drug Corporation
operations and our corporate functions as intended without functional
problems, unanticipated delays and/or cost overruns; success of
integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United
Kingdom and elsewhere outside of the United States, including changes
and/or potential changes in Canadian provincial legislation affecting
pharmaceutical product pricing or service fees or regulatory action
by provincial authorities in Canada to lower pharmaceutical product
pricing and service fees; the impact of divestitures or the acquisition
of businesses that do not perform as we expect or that are difficult
for us to integrate or control; our inability to successfully complete
any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect
our tax positions and/or our tax liabilities or adverse resolution of
challenges to our tax positions; increased costs of maintaining, or
reductions in our ability to maintain, adequate liquidity and financing
sources; volatility and deterioration of the capital and credit markets;
and other economic, business, competitive, legal, tax, regulatory
and/or operational factors affecting our business generally. Certain
additional factors that management believes could cause actual
outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors)
in the Company’s Annual Report on Form 10-K for the fiscal year
ended September 30, 2011 and elsewhere in that report and (ii) in
other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.